Analysed PRELUDE THERAPEUTICS INC (PRLD:NASDAQ) News Sources
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026
10-03-2026
yahoo.com
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting
17-03-2026
yahoo.com
Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer
15-04-2026
yahoo.com
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026
20-04-2026
yahoo.com
Prelude Therapeutics (PRLD) Presents Preclinical Data for KAT6A Degarader PRT13722 in Breast Cancer
01-05-2026
yahoo.com
Wall Street Analysts Think Prelude Therapeutics (PRLD) Could Surge 33.59%: Read This Before Placing a Bet
08-05-2026
yahoo.com
Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
12-05-2026
yahoo.com
What is the current price of PRELUDE THERAPEUTICS INC (PRLD:NASDAQ)?
The current price of PRELUDE THERAPEUTICS INC (PRLD:NASDAQ) is $4.16.
PRELUDE THERAPEUTICS INC (PRLD:NASDAQ) absolute price change since previous trading day?
The absolute price change of PRELUDE THERAPEUTICS INC (PRLD:NASDAQ) since the previous trading day is $0.07.
PRELUDE THERAPEUTICS INC (PRLD:NASDAQ) percentage price change since previous trading day?
The percentage price change of PRELUDE THERAPEUTICS INC (PRLD:NASDAQ) since the previous trading day is 1.7115%.
What is the most recent average sentiment score for PRELUDE THERAPEUTICS INC (PRLD:NASDAQ)?
The most recent average sentiment score for PRELUDE THERAPEUTICS INC (PRLD:NASDAQ) is 78 out of 100.
What is the most recent average sentiment for PRELUDE THERAPEUTICS INC (PRLD:NASDAQ)?
The most recent sentiment for PRELUDE THERAPEUTICS INC (PRLD:NASDAQ) is .
SEC-8K** Filing Available For PRELUDE THERAPEUTICS INC (PRLD:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.